In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug

Investigational New Drugs

Volumn 25, Issue 1, 2007, Pages 9-19

  Brandon, Esther F A ^a   Sparidans, Rolf W ^a   Van Ooijen, Ronald D ^a   Meijerman, Irma ^a   Lazaro, Luis Lopez ^b   Manzanares, Ignacio ^b   Beijnen, Jos H ^a,c   Schellens, Jan H M ^a,d  

^a UTRECHT UNIVERSITY   (Netherlands)

^b PHARMAMAR S A   (Spain)

^c SLOTERVAART HOSPITAL   (Netherlands)

^d NETHERLANDS CANCER INSTITUTE   (Netherlands)

Author keywords

Aplidine; Cytochrome P450 (CYP); Human biotransformation; Human cell lines; Human liver fractions; Phase II enzymes; Supersomes

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOXYLESTERASE; CHLORZOXAZONE; COUMARIN; CYTOCHROME P450; CYTOCHROME P450 2A6; CYTOCHROME P450 3A4; CYTOCHROME P450 4A11; CYTOCHROME P450 INHIBITOR; DEHYDRODIDEMNIN B; DRUG METABOLITE; GLUCURONOSYLTRANSFERASE; RITONAVIR;

ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG HALF LIFE; DRUG INHIBITION; DRUG METABOLISM; DRUG STRUCTURE; DRUG TRANSFORMATION; FEMALE; GLUCURONIDATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN CELL; LIVER CYTOSOL; LIVER MICROSOME; MALE; PLASMA; PRIORITY JOURNAL; SEX DIFFERENCE;

ANTINEOPLASTIC AGENTS; ARYL HYDROCARBON HYDROXYLASES; CELL LINE, TUMOR; CELL SURVIVAL; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; CYTOSOL; DEPSIPEPTIDES; FEMALE; GLUCURONOSYLTRANSFERASE; HALF-LIFE; HUMANS; LIVER; MALE; METABOLIC DETOXICATION, PHASE II; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; NITROPHENOLS; PHENYLMETHYLSULFONYL FLUORIDE; SPECTROPHOTOMETRY, ULTRAVIOLET; SUBCELLULAR FRACTIONS;

EID: 33750483926     PISSN: 01676997     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10637-006-7589-7     Document Type: Article

References (47)

1. Urdiales JL, Morata P, Nunez De Castro I, Sanchez-Jimenez F (1996) Antiproloferative effect of dehydrodidemnin B (DDB), a depsipeptide isolated from Mediterranean tunicates. Cancer Lett 102:31-37
2. Faircloth G, Hanauske A, Depenbrock H, Peter R, Crews CM, Manzanares I, Meely K, Grant W, Jimeno J (1997) Pre-clinical characterization of aplidine, a new marine anticancer depsipeptide. Proc Am Assoc Cancer Res 38:692
3. Erba E, Ronzoni S, Bergamaschi D, Bassano L, Desiderio MA, Faircloth G, Jimeno J, D'Incalci M (1999) Mechanism of antileukemic activity of aplidine. Proc Am Assoc Cancer Res 40:3
4. Broggini M, Marchini S, D'Incalci M, Faircloth GT, Jimeno J (1999) Changes in gene expression in tumor cells exposed to the two marine compounds, ET-743 and aplidine, by using cDNA microarrays. Proc Am Assoc Cancer Res 10:310
5. Jimeno JM (2002) A clinical armamentarium of marine-derived anti-cancer compounds. Anti-Cancer Drugs 13 (suppl. 1):S15-S19
6. Depenbrock H, Peter R, Faircloth GT, Manzanares I, Jimeno J., Hanauske AR (1998) In vitro activity of aplidine, a new marine-derived anti-cancer compound, on freshly explanted clonogenic human tumour cells and haematopoietic precursor cells. Br J Cancer 78:739-744
7. Raymond E, Paz-Ares L, Izquierdo M, Belanger K, Maroun J, Bowman A, et al. (2001) Phase I trials with aplidine, a new marine derived anticancer compound. Eur J Cancer 37 (suppl. 6):S32
8. Faivre S, Chieze S, Delbaldo C, Ady-Vago N, Guzman C, Lopez-Lazaro L, et al. (2005) Phase I and pharmacokinetic study of aplidine, a new marine cyclodepsipeptide in patients with advanced malignancies. J Clin Oncol 23:7871-7880.
9. Schwartsmann G, Brondani da Rocha A, Mattei J, Martins Lopez R (2003) Marine-derived anticancer agents in clinical trials. Expert Opin Investig Drugs 12:1-17
10. Brandon EFA, van Ooijen RD, Sparidans RW, López Lázaro L, Heck AJR, Beijnen JH, Schellens JHM (2005) Structure elucidation of aplidine metabolites formed in vitro by human liver microsomes using triple quadrupolemass spectrometry. J Mass Spectrom 40:821-831
11. Brandon EFA, Sparidans RW, Guijt K-J, Löwenthal S, Meijerman I, Beijnen JH, Schellens JHM (2006) In vitro chracterization of the human biotransformation an CYP reaction phenotype of ET-743 (Yondelis®, Trabectedin®), a novel marine anti-cancer drug. Invest New Drugs 24:3-14
12. Higgins JD III, Neely L, Fricker S (1993) Synthesis and cytotoxicity of some cyclometallated palladium complexes. J Inorg Biochem 49:149-156
13. Zucchetti M, Lopez-Lazaro L, Celli N, Cicchella B, Twelves C, Paz-Agres L, Izquirdo MA, Bowman A, Raymond E, Maroun J, Belanger K, D'Incalci M (2000) Clinical pharmacokinetics (PK) of aplidine (APL) in patients with solid tumors and non-Hodgkin lymphomas. Proc Am Assoc Cancer Res 30:4932
14. Celli N, Mariana B, Di Carlo F, Zucchetti M, Lopez-Lazaro L, D'Incalci M, Rotilio D (2004) Determination of aplidin®, a marine-derived anticancer drug, in human plasma, whole blood and urine by liquid chromatography with electrospray ionisation tandem mass spectrometric detection. J Pharmaceut Biomed Anal 34:619-630
15. Sparidans RW, Kettenes-van den Bosch JJ, van Tellingen O, Nuyen B, Henrar REC, Jimeno JM, Faircloth G, Floriano P, Rinehart KL, Beijnen JH (1999) Bioanalysis of aplidine, a newmarin antitumoral depsipeptide, in plasma by high performance liquid chromatography after drivatization with trans-4′- hydrazino-2-stilbazole. J Chromatogr B 729:43-53
16. Sparidans RW, Schellens JHM, López-Lázaro L, Jimeno JM, Beijnen JH (2004) Liquid chromatographic assauy for the cyclic depsipeptide aplidine, a newmarine antitumor drug, in whole blood using derivatization with trans-4′-hydrazino-2-stilbazole. Biomed Chromatogr 18:16-20
17. Curry SH (1974) Drug disposition and pharmaconkinetics with a consideration of pharmacological and clinical relationships. Blackwell Scientific Publications, Oxford, pp 42-48
18. Gibson GG, Skett P (1994) Introduction to drug metabolism. Blackie Academic and Professional, London, pp 1-34
19. Guengerich FP (2001) Uncommon P450-catalyzed reactions. Curr Drug Metab 2:93-115
20. Gentest Cytochrome P450 database. www.gentest.com/human_p450_database. (accessed July 2003).
21. Ikeda K, Yoshisue K, Matsushima E, Nagayama S, Kobayashi K, Tyson CA, Chiba K, Kawaguchi Y (2000) Bioactivation of tegafur to 5-fluorouracil is catalyzed by cytochrome P-450 2A6 in human liver microsomes in vitro. Clin Cancer Res 6:4409-4415
22. Donato MT, Jimenez N, Castell JV, Gomez-Lechon MJ (2004) Fluorescence-based assays for screening nine cytochrome P450 (P450) activities in intact cells expressing individual human P450 enzymes. Drug Metab Dispos 32:699-706
23. Yu LJ, Matias J, Scudiero DA, Hite KM, Monks A, Sausville EA, Waxman DJ (2001) P450 enzyme expression patterns in the NCI human tumor cell line panel. Drug Metab Dispos 29:304-312
24. Ko JW, Desta Z, Soukhova NV, Tracy T, Flockhart DA (2000) In vitro inhibition of the cytochrome P450 (CYP450) system by the antiplatelet drug ticlopidine: Potent effect on CYP2C19 and CYP2D6. Br J Clin Pharmacol 49:343-351
25. Zhou S, Paxton JW, Tingle MD, Kestell P (2000) Identification of the human liver cytochrome P450 isoenzyme responsible for the 6-methylhydroxylation of the novel anticancer drug 5,6-dimethylxanthenone-4-acetic acid. Drug Metab Dispos 28:1449-1456
26. Lasker JM, Chen WB, Wolf I, Bloswick BP, Wilson PD, Powell PK (2000) Formation of 20-hydroxyeicosatetraenoic acid, a vasoactive and natriuretic eicosanoid, in human kidney. Role of Cyp4F2 and Cyp4A11. J Biol Chem 275:4118-4126
27. Kumar GN, Dykstra J, Roberts EM, Jayanti VK, Hickman D, Uchic J, Yao Y, Surber B, Thomas S, Granneman GR (1999) Potent inhibition of the cytochrome P-450 3A-mediated human liver microsomal metabolism of a novel HIV protease inhibitor by ritonavir: a positive drug-drug interaction. Drug Metab Dispos 27:902-908
28. Tanaka E (1999) Gender-related differences in pharmacokinetics and their clinical significance. J Clin Pharm Ther 24:339-346
29. Wormhoudt LW, Commandeur JNM, Vermeulen NPE (1999) Genetic polymorphisms of human N-acetyltransferase, cytochrome P450, glutathione-S-transferase, and epoxide hydrolase enzymes: relevance to xenobiotic metabolism and toxicity. Crit Rev Toxicol 29:59-124
30. Knasmuller S, Parzefall W, Sanyal R, Ecker S, Schwab C, Uhl M, et al. (1998) Use of metabolically competent human hepatoma cells for the detection of mutagens and antimutagens. Mutat Res 402:185-202
31. Brandon EFA, Raap CD, Meijerman I, Beijnen JH, Schellens JHM (2003) An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons. Toxicol Appl Pharmacol 189:233-246
32. Wilkening S, Bader A (2003) Influence of culture time on the expression of drug-metabolizing enzymes in primary human hepatocytes and hepatoma cell line HepG2. J Biochem Molec Toxicol 17:207-213
33. Grant H, Duthie SJ, Gray AG, Burke D (1988) Mixed function oxidase and UDP glucuronyltransferase activities in the human Hep G2 hepatoma cell line. Biochem Pharmacol 37:4111-4116
34. Fardel O, Morel F, Ratanasanh D, Fautrel A, Beaune P, Guillouzo A (1992) Expression of drug metabolizing enzymes in human HepG2 hepatoma cells. Cellular Molec Aspects Cirrhosis 216:327-330
35. Perego P, Paolicchi A, Tongiani R, Pompella A, Tonarelli P, Carenni N, et al. (1997) The cell-specific anti-proliferative effect of reduced glutathione is mediated by gamma-glutamyl transpeptidase-dependent extracellular pro-oxidant reactions. Int J Cancer 71:246-250
36. 1H NMR study. Br J Cancer 86:1180-1187
37. Tucker GT (1992) The rational selection of drug interaction studies: implication of recent advantages in drug metabolism. Int J Clin Pharmacol Ther Toxicol 30:550-553
38. Levy RH, Thummel KE, Trager WF, Hansten PD, Eichelbaum M (2000) Metabolic drug intractions. Lippincott Williams and Wilkins, Philadelphia
39. Desai PB, Duan JZ, Zhu YW, Kouzi S (1998) Human liver microsomal metabolism of paclitaxel and drug interactions. Eur J Drug Metab Pharmacokinet 23:417-424
40. Vecht CJ, Wagner GL, Wilms EB (2003) Interactions between antiepileptic and chemotherapeutic drugs. Lancet Neurology 2:404-409
41. MacLeod SL, Nowell S, Massengill J, Jazieh A, McClure G, Plaxco J, Kadlubar FF, Lan NP (2000) Cancer therapy and polymorphisms of cytochrome P450. Clin Chem Lab Med 38:883-887
42. Eiselt R, Domanski TL, Zibat A, Mueller R, Presecan-Siedel E, Hustert E, Zanger UM, Brockmoller J, Klenk HP, Meyer UA, Khan KK, He YA, Halpert JR, Wojnowski L (2002) Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-458
43. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J (2001) CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 48:1668-1671
44. Tukey RH, Strassburg CP (2000) Human UDP-glucuronosyltransferases: Metabolism, expression, and disease. Annu Rev Pharmacol Toxicol 40:581-616
45. MacKenzie PI, Miners JO, McKinnon RA (2000) Polymorphisms in UDP glucuronosyltransferase genes: Functional consequences and clinical relvance. Clin Chem Lab Med 38:889-892
46. Glatt H, Boeing H, Engelke CEH, Ma L, Kuhlow A, Pabel U, Pomplun D, Teubner W, Meinl W (2001) Human cytosolic sulphotransferases: Genetics, characterization, toxicological aspects. Mutat Res 482:27-40
47. Coughtrie MWH (2002) Sulfation trough the looking glass - recent advances in sulfotransferase research for the curious. Pharmacogenomics J 2: 297-308